An observational study in Radiation Pneumonitis, sponsored by Huazhong University of Science and Technology. Recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-06.
Sponsored by Huazhong University of Science and Technology · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Radiation Pneumonitis with a site in China — 9 open to participants now, 11 under way, none of them phase 3. Radiation Pneumonitis · China.
Among the 16 studies in Radiation Pneumonitis with a site in China, this one is the only one that started in 2021, is one of 6 observational ones, reaches primary completion later than 6 of the 10 other live ones, and was the 7th registered.
40 studies on the registry are indexed under Radiation Pneumonitis; 17 are open to participants now.
Browse Radiation Pneumonitis studies →9 of the 16 studies in Radiation Pneumonitis with a site in China are open now. Recruiting first, the newest first:
The Second Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 18–85
Fifth Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 17–70
Second Hospital of Shanxi Medical University · Sites in China
Ages 18+
Xinqiao Hospital of Chongqing · Sites in China
Ages 18–80
Guangdong Provincial People's Hospital · Sites in China
Ages 18–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 12 Radiation Pneumonitis studies recruiting now, 6 (50%) set no upper age limit and 3 (25%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7
First in 2008; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 160 across 15 observational studies indexed under Radiation Pneumonitis.
Median enrollment 72 across the 10 interventional studies, 201 across the 6 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 16 has an industry lead sponsor. The 10 most frequent:
Huazhong University of Science and Technology is the lead sponsor of 248 studies on the registry; 62 are open to participants now.
Huazhong University of Science and Technology has 2 studies filed under Radiation Pneumonitis — fewer than ten, so there is no comparison to draw.
2 of the studies in Radiation Pneumonitis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07339644The Second Affiliated Hospital of Chongqing Medical UniversityFunctional Lung Avoidance Radiotherapy Guided by 4DCT Pulmonary Ventilation Function Imaging: A Prospective Single-arm Clinical Study | 2026-12-24 |
| NCT05189496Guangdong Provincial People's HospitalHyperbaric Oxygen in the Prevention of Radiation Pneumonitis | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Radiation Pneumonitis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Radiation pneumonitis is the main dose-limiting toxicity of thoracic radiotherapy, which can affect life quality, survival, and the tumor-controlling effects of patients receiving thoracic radiotherapy.
The purpose of this study is to:
Lung cancer patients treated with thoracic radiotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lung cancer patients treated with thoracic radiotherapy
Other: Blood Samples for Biomarkers
blood sample to be taken at baseline, during radiotherapy, and after radiotherapy
Radiation pneumonitis
radiation pneumonitis grade \>=2 or 3 graded by CTCAE4.0. \[Time Frame: 12 months after radiotherapy\]
Time frame: 12 months after radiotherapy
Overall Survival
A long-term follow up will be scheduled to allow a complete survival analysis.
Time frame: 5 years after radiotherapy
Other injuries induced by radiotherapy
Assessment of other common injuries induced by thoracic radiotherapy including injuries in heart, skin, and esophagus according to CTCAE4.0.
Time frame: 5 years after radiotherapy
Started Feb 2021 (actual). Primary completion is estimated for Sep 2026, 66 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Huazhong University of Science and Technology →